According to Cushman & Wakefield, H3 Biomedicine, a new company owned by Eisai has leased 49,898 s/f at 300 Technology Sq. in Alexandria's Technology Sq. Cushman & Wakefield's director Juliette Reiter and executive director Mark Winters represented both the landlord, an affiliate of Alexandria Real Estate Equities, Inc., and the tenant.
Alexandria's Technology Sq. features seven laboratory and office buildings totaling 1.2 million s/f. Technology Sq. is a collaborative campus setting with a tree-lined courtyard and convenient on-site amenities. 300 Technology Sq. was built in 2001 and offers tenants more than 175,000 s/f of office and laboratory space. Catalyst, a new conference center and restaurant located on the first floor, is scheduled to open this summer as well.
H3 Biomedicine is a new biotechnology company focused on the discovery of innovative new drugs to fight cancer. Utilizing exciting new knowledge coming from cancer genome sequencing efforts and employing a unique business model, H3 Biomedicine aspires to forge a new path toward cancer drug discovery. H3 Biomedicine is actively recruiting the balance of its scientific team, which will be located in Cambridge.
"We are confident that H3 Biomedicine is going to produce some very exciting science," said Reiter. "Alexandria's Technology Sq. is a great fit for this new venture as the campus setting will allow them to take full advantage of the science-driven clustering in Kendall Sq."